PA-25-123: Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on May 7, 2025.
From the official notice on Grants.gov, last changed October 10, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR21
- Clinical trialsNot allowed
- R21, Exploratory/Developmental Research Grant. Early, exploratory ideas that may not have preliminary data yet, usually for up to two years. Other open R21 notices.
Application due dates, page limits and budget limits are set in the notice. Read PA-25-123 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-22-084 | January 21, 2022 | Closed November 16, 2024 | Closed |
Key dates
| Posted | October 10, 2024 |
|---|---|
| Deadline | May 7, 2025 |
| Archived by Grants.gov | June 12, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the program's money (66% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PA-25-123 still open?
No. It closed on May 7, 2025.
Who can apply for Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)?
Closed May 7, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has won Cancer Cause and Prevention Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.
Similar open grants
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)